Pulse Biosciences, Inc. (NASDAQ:PLSE - Get Free Report) shares passed below its 50-day moving average during trading on Wednesday . The stock has a 50-day moving average of $17.56 and traded as low as $15.29. Pulse Biosciences shares last traded at $15.74, with a volume of 70,354 shares traded.
Analysts Set New Price Targets
Separately, StockNews.com raised shares of Pulse Biosciences to a "sell" rating in a research note on Friday, September 20th.
Get Our Latest Research Report on PLSE
Pulse Biosciences Price Performance
The firm's fifty day simple moving average is $17.56 and its 200 day simple moving average is $13.24. The company has a market capitalization of $861.51 million, a price-to-earnings ratio of -19.20 and a beta of 1.74.
Institutional Inflows and Outflows
Several hedge funds and other institutional investors have recently made changes to their positions in PLSE. Vanguard Group Inc. boosted its holdings in shares of Pulse Biosciences by 28.8% in the first quarter. Vanguard Group Inc. now owns 847,212 shares of the company's stock worth $7,379,000 after buying an additional 189,227 shares during the period. Griffin Asset Management Inc. boosted its holdings in shares of Pulse Biosciences by 15.7% during the first quarter. Griffin Asset Management Inc. now owns 300,320 shares of the company's stock worth $2,616,000 after purchasing an additional 40,700 shares during the period. Westside Investment Management Inc. boosted its holdings in shares of Pulse Biosciences by 97.8% during the second quarter. Westside Investment Management Inc. now owns 63,600 shares of the company's stock worth $712,000 after purchasing an additional 31,440 shares during the period. PNC Financial Services Group Inc. acquired a new stake in shares of Pulse Biosciences during the fourth quarter worth approximately $242,000. Finally, Cetera Advisors LLC acquired a new stake in shares of Pulse Biosciences during the first quarter worth approximately $109,000. 76.95% of the stock is currently owned by institutional investors and hedge funds.
Pulse Biosciences Company Profile
(
Get Free Report)
Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.
See Also
Before you consider Pulse Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pulse Biosciences wasn't on the list.
While Pulse Biosciences currently has a "hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
